| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/15/2006 | US20060128722 Indoles useful in the treatment of androgen-receptor related diseases |
| 06/15/2006 | US20060128721 Novel formulations of opioid-based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives |
| 06/15/2006 | US20060128720 Inhibition of cell death responses induced by oxidative stress |
| 06/15/2006 | US20060128719 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea |
| 06/15/2006 | US20060128718 Tetrahydropyridazine derivatives having a pesticidal effect |
| 06/15/2006 | US20060128717 Therapeutic agents useful for treating pain |
| 06/15/2006 | US20060128716 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
| 06/15/2006 | US20060128715 Oxime derivative hydroxyethylamine aspartyl-protease inhibitors |
| 06/15/2006 | US20060128714 Lipoic acid, vitamin C, vitamin E, arachidonic acid, folic acid, and N-acetylcysteine as a glutathione precursor; may also contain myoinositol; hyperglycemia-associated abnormalities: increased reactive oxygen species generation, abnormal membrane phospholipid metabolism, decreased glutathione synthesis |
| 06/15/2006 | US20060128713 (6-Chloro-3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridin-2-yl)-(2-isopropoxy-5-methanesulfonyl-phenyl)-methanone; glyicne transporter 1 (GlyT-1) and N-methyl-D-aspartate (NMDA) receptors inhibitor; psychoses, schizophrenia, attention deficit disorders, Alzheimer's disease; cognition activator |
| 06/15/2006 | US20060128712 Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups |
| 06/15/2006 | US20060128711 derivatives of ecteinascidins, particularly ecteinascidin 736, used for the treatment of lung, colon, kidney, prostate, cervical, ovarian, breast or pancreatic cancer, leukaemia or melanoma in mammals; reduced systemic toxicity and improved pharmacokinetics |
| 06/15/2006 | US20060128710 Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| 06/15/2006 | US20060128709 N-(4-Chlorophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine for example; inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1; angiogenesis inhibitors; anticancer agents; diseases associated with signal transduction pathways operating through growth factor receptors |
| 06/15/2006 | US20060128708 Antagonizing an adenosine A2A receptor to ameliorate one or more components of addictive behavior |
| 06/15/2006 | US20060128707 Imidazotriazinone derivatives as pde 7 (phosphodiesterase 7) inhibitors |
| 06/15/2006 | US20060128706 Apoptosis promoters |
| 06/15/2006 | US20060128705 Method of treating chronic fatigue syndrome |
| 06/15/2006 | US20060128704 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists |
| 06/15/2006 | US20060128703 crystalline linezolid form III (N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide) an antibacterial agent; thermal stability |
| 06/15/2006 | US20060128702 Heterocyclic and bicyclic compounds, compositions and methods |
| 06/15/2006 | US20060128701 N-{4-[ethyl-(2-hydroxy-ethyl)-amino]-phenyl}-2-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1- yl)-piperidin-1-yl]-acetamide; Eating disorders; CNS disorders; antidiabetic agents; psychological disorders; antiepileptic, antiinflammatory agents, autoimmune diseases; neuropeptide Y5 (NPY5) receptor antagonists |
| 06/15/2006 | US20060128700 e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia |
| 06/15/2006 | US20060128699 Novel pharmacophore for the discovery and testing of na,k-atpase inhibitor compositions and methods for their use in treating cardiovascular diseases and conditions |
| 06/15/2006 | US20060128697 Disease associated with AMPA (alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) flux; cognitive disorders, anxiety or depressive syndromes, neurodegenerative diseases; N-(2-{4-[(5,5-dioxido-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazin-7-yl)oxy]phenyl}ethyl)methanesulphonamide |
| 06/15/2006 | US20060128696 Treating seizures using ice inhibitors |
| 06/15/2006 | US20060128695 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| 06/15/2006 | US20060128694 Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| 06/15/2006 | US20060128693 Pyrrolobenzodiazepines |
| 06/15/2006 | US20060128692 Non nucleoside reverse transcriptase inhibitors |
| 06/15/2006 | US20060128691 gamma-aminobutyric acid GABA receptors inverse agonists ; Alzheimer's disease, cognition enhancers; 10-methyl-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine |
| 06/15/2006 | US20060128690 Amine derivative |
| 06/15/2006 | US20060128689 N-(7-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N'-1H-indazol-4-ylurea, used to treat or prevent pain, inflammatory thermal hyperalgesia, bladder overactivity and urinary incontinence |
| 06/15/2006 | US20060128688 Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight |
| 06/15/2006 | US20060128687 Lactam glycogen phosphorylase inhibitors and method of use |
| 06/15/2006 | US20060128686 Preparation of pyridonecarboxylic acid antibacterials |
| 06/15/2006 | US20060128685 Pyrazole derivative |
| 06/15/2006 | US20060128684 Anthranilic acid amide derivatives and their pharmaceutical use |
| 06/15/2006 | US20060128683 Novel use of porphyrin derivatives |
| 06/15/2006 | US20060128682 Compounds and methods for the treatment of cancer |
| 06/15/2006 | US20060128681 Novel rho inhibitors |
| 06/15/2006 | US20060128680 porosity; nanostructure |
| 06/15/2006 | US20060128679 Method for treatment of dysmenorrhea |
| 06/15/2006 | US20060128678 Manganese based organometallic complexes, pharmaceutical compositions and dietetic products |
| 06/15/2006 | US20060128677 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system |
| 06/15/2006 | US20060128676 Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain |
| 06/15/2006 | US20060128675 Method for monitoring the effectiveness of teracycline in the treatment of asthma |
| 06/15/2006 | US20060128674 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; antiviral and antitumor agents |
| 06/15/2006 | US20060128673 Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions |
| 06/15/2006 | US20060128672 Methods for the administration of amifostine and related compounds |
| 06/15/2006 | US20060128671 Compositions containing a combination of a creatine compound and a second agent |
| 06/15/2006 | US20060128669 3-(4-Fluorobenzyl)-8-hydroxy-quinoline-5,7-dicarboxylic acid 7-methylester; against Human T Cell leukemia virus, Feline and Simian immunodeficiency viruses, AIDS and related clinical symptoms |
| 06/15/2006 | US20060128668 Formed by selective phosphorylation of phenpanstatin with tetrabutylammonium dihydrogen phosphate and dicyclohexylcarbodiimide in pyridine followed by cation exchange; cancer cell inhibitors |
| 06/15/2006 | US20060128667 Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators |
| 06/15/2006 | US20060128666 Use of sphingomyelin and lyso-sphingomyelin as absorption enhancers |
| 06/15/2006 | US20060128665 Marine lipid compositions |
| 06/15/2006 | US20060128664 Aryl boronic acids for treating obesity |
| 06/15/2006 | US20060128663 Aryl boronate functionalized polymers for treating obesity |
| 06/15/2006 | US20060128662 Novel compounds for treatment of obesity |
| 06/15/2006 | US20060128661 Novel substituted 1H-pyrrolo[2,3-b]pyridines and preparation thereof |
| 06/15/2006 | US20060128660 FK228 analogs and methods of making and using the same |
| 06/15/2006 | US20060128659 Sulfotransferase inhibitors |
| 06/15/2006 | US20060128658 Biocompatible dialysis fluids containing icodextrins |
| 06/15/2006 | US20060128657 Selected betaines and their uses |
| 06/15/2006 | US20060128656 Charged phospholipid compositions and methods for their use |
| 06/15/2006 | US20060128655 Use of hyaluronic acid or its derivatives to enhance delivery of antineoplastic agents |
| 06/15/2006 | US20060128654 Pharmaceutical formulation of cytidine analogs and derivatives |
| 06/15/2006 | US20060128653 Pharmaceutical formulation of decitabine |
| 06/15/2006 | US20060128652 Purine derivatives and methods of use thereof |
| 06/15/2006 | US20060128651 Methods and compositions for modulating drug activity through telomere damage |
| 06/15/2006 | US20060128646 Antisense design |
| 06/15/2006 | US20060128644 Use of mob-5 in pain |
| 06/15/2006 | US20060128643 Compositions containing a combination of a creatine compound and a second agent |
| 06/15/2006 | US20060128641 Levamisole, avermectins or similar in pyrrolidone solvent |
| 06/15/2006 | US20060128640 Combination of a taxane and a cyclin-dependent kinase |
| 06/15/2006 | US20060128639 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 06/15/2006 | US20060128638 Treating atheroma, tumors and other neoplastic tissue; treating atherosclerotic inflammation; forming a complexes with a reducing agent, penetrate and accumulate more rapidly in tumor cells, plaque, increase drug in intracellular concentration; increase photosensitivity |
| 06/15/2006 | US20060128637 Phenolic acid complexes of hyoscyamine and process for preparing the same |
| 06/15/2006 | US20060128636 Breast cancer resistance protein (bcrp) inhibitor |
| 06/15/2006 | US20060128635 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
| 06/15/2006 | US20060128634 Alpha, alpha-disubstituted benzylglycine derivatives as HIV protease inhibitors |
| 06/15/2006 | US20060128633 Colchinol derivatives as vascular damaging agents |
| 06/15/2006 | US20060128624 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| 06/15/2006 | US20060128622 Therapeutic formulations of keratinocyte growth factor |
| 06/15/2006 | US20060128621 Pharmaceutical composition of hydrophobically modified hedgehog proteins and their use |
| 06/15/2006 | US20060128617 Oligoribonucleotide or peptidic nucleic acid inhibiting function of hepatitis c virus |
| 06/15/2006 | US20060128611 Composition for enzyme inhibition |
| 06/15/2006 | US20060128608 Novel chemical compounds and their use |
| 06/15/2006 | US20060128605 Preventives/remedies for snore or respiratory disturbances during sleep |
| 06/15/2006 | US20060128003 Therapeutic agents for low HDL-cholesterolemia |
| 06/15/2006 | US20060127980 Human excitatory amino acid transporter-2 gene promoter and uses thereof |
| 06/15/2006 | US20060127927 Mammalian IAP gene family, primers, probes, and detection methods |
| 06/15/2006 | US20060127910 Bpl1 as an antifungal target |
| 06/15/2006 | US20060127894 Protein associated with cell growth, differentiation, and death |
| 06/15/2006 | US20060127873 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 06/15/2006 | US20060127517 administering to mammal a composition comprising a first component selected from dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, a second component selected from the group consisting of rosemary, an extract derived from rosemary |
| 06/15/2006 | US20060127516 Modulation of inflammation by hops fractions and derivatives |
| 06/15/2006 | US20060127515 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response |
| 06/15/2006 | US20060127514 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response |
| 06/15/2006 | US20060127513 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response |